Exhibiting at FOOD INGREDIENTS CHINA 2025

ATK Biotech Co., Ltd., headquartered in Chuzhou, Anhui Province, China, is a cutting-edge biotechnology company specializing in the production of high-purity nutritional lipids and functional ingredients. As a technology-driven manufacturer, ATK Biotech is committed to advancing health through science, offering innovative bio-based solutions for infant nutrition, dietary supplements, and functional foods.

Core Business and Product Offerings

ATK Biotech's primary product segments are structured around high-value nutritional compounds derived through fermentation, enzymatic processes, and precision refining:

• Polyunsaturated Fatty Acids (PUFAs):

  • DHA Algal Oil: Plant-based docosahexaenoic acid sourced from microalgae for infant formula and brain health.
  • ARA Oil: Arachidonic acid extracted for infant nutrition applications.
  • DHA Powder and ARA Powder: Microencapsulated powders designed for easy incorporation into dry blends and supplements.

• Functional Ingredients:

  • OPO Structured Lipids: Human milk fat analogs supporting infant fat and calcium absorption.
  • Functional Whey Protein: Bioactive protein concentrates designed for immunity and muscle recovery.
  • Probiotics: Viable microbial strains for digestive and immune support.
  • Allulose: Low-calorie rare sugar with prebiotic and blood sugar-modulating properties.
  • Human Milk Oligosaccharides (HMOs): Prebiotics that mimic the function of natural breast milk to support infant gut microbiota.

These products are used across a wide range of applications including infant formula, adult nutrition, nutraceuticals, and medical foods.

Specialization and Unique Selling Proposition

ATK Biotech distinguishes itself through its technical expertise in lipid science and infant nutrition innovation. The company's proprietary fermentation and refining technologies enable:

• High-purity production of DHA and ARA oils from algal and microbial sources
• Customized powder formulations with optimal bioavailability and stability
• Structured lipid synthesis (OPO) tailored for infant formula developers
• Clinical-grade HMOs with high structural fidelity to those found in human breast milk

The company’s research is closely aligned with pediatric nutrition science, giving it a unique positioning in the Asia-Pacific infant formula supply chain.

Target Markets and Export Activities

ATK Biotech exports its ingredients globally, serving both branded product manufacturers and contract manufacturers in:

• Southeast Asia: Thailand, Vietnam, Malaysia
• East Asia: South Korea, Japan
• Europe: Netherlands, Germany, Switzerland
• North America: United States and Canada

Its DHA algal oil and OPO lipids are particularly favored by infant formula manufacturers, while Allulose and whey protein are increasingly used by functional food and supplement companies.

Export records and online trade platforms indicate a rising international demand for their DHA and structured lipid series, with growing inquiries from EU-based baby nutrition brands and clean-label supplement formulators.

Financials and Operational Capacity

Though ATK Biotech is privately held, its production and R&D infrastructure point to a mid-to-large-scale operation with vertical integration. Key indicators include:

• Annual production capacity of several hundred tons of DHA and ARA oils
• Multiple microencapsulation and fermentation units
• GMP-certified clean rooms for infant-grade ingredients
• Dedicated R&D and application teams supporting product customization and regulatory documentation

The company continues to invest in clinical partnerships and new bioactive development, positioning itself as a future-ready supplier in the premium nutrition segment.

Certifications and Regulatory Compliance

ATK Biotech adheres to stringent international standards for food safety and product efficacy, holding or working toward:

• ISO 22000 and HACCP certifications
• Halal Certification
• China FDA and CFDA Registration
• European Union Novel Food Registration (DHA and HMOs)
• GRAS (Generally Recognized as Safe) for ingredients like Allulose and DHA in the U.S.

The company supports its clients with full dossiers for regulatory submissions, nutritional labeling, and functional claim substantiation.

Capabilities and Infrastructure

ATK Biotech’s facilities are built to support both core production and product innovation, including:

• Advanced fermentation tanks for microbial biosynthesis of lipids and HMOs
• Microencapsulation systems for oil and probiotic stabilization
• High-purity refining lines for lipids
• Pilot production suites for ingredient prototyping
• Analytical labs equipped with GC, HPLC, LC-MS/MS, and microbial platforms

The company also operates an infant nutrition R&D center, enabling partnerships with leading academic institutions and pediatric research centers.

Customer Testimonials

Feedback from international nutrition brands and OEM partners emphasizes ATK Biotech’s innovation and product quality:

“Their DHA powder offers excellent dispersibility and is ideal for our dry-blend infant formulas.”
– Technical Director, Infant Nutrition Company, Vietnam

“Reliable quality and full documentation support made our regulatory filing process seamless.”
– Regulatory Affairs Manager, European Medical Nutrition Brand

Recognitions and Industry Participation

ATK Biotech is actively involved in:

• FIC (Food Ingredients China)
• Hi & Fi Asia-China
• CPhI and Nutraceutical Asia

The company collaborates with research institutions on topics like structured lipids, probiotic delivery systems, and infant metabolic health, and has been recognized as a high-tech enterprise in Anhui Province.

Summary

ATK Biotech Co., Ltd. is a pioneering force in China’s bioscience landscape, offering premium-quality DHA, structured lipids, and functional ingredients for the next generation of health and nutrition products. With its science-driven approach, regulatory excellence, and expanding global footprint, ATK Biotech continues to shape the future of infant and functional nutrition through innovation and integrity.